UK backs physics-based AI startup seeking faster drug discovery
British public investment and computing access will support Potential Sciences, a startup developing physics-based tools for molecular design.
Photo credit and license
Photo: Saidelo / Wikimedia Commons / CC BY-SA 4.0 (unmodified photograph) · Image source · License: CC BY-SA 4.0The UK government said on 5 November that its Sovereign AI programme is backing Potential Sciences, a British startup developing artificial intelligence tools for chemical modelling. The support includes an investment in an eight-figure funding round and access to national computing resources. The government did not disclose the amount of its own investment.
Potential Sciences is pursuing calculations grounded in the laws of physics rather than relying primarily on collections of experimental results. According to the company, software designed for graphics processors could make certain high-accuracy chemical calculations up to 100 times more efficient. That figure is a company claim about computational efficiency, not a demonstrated reduction in the cost or time of bringing a medicine to patients.
The company hopes to use the approach to explore candidate molecules and chemical processes that are expensive to investigate through conventional laboratory methods. Drug discovery, however, requires much more than molecular calculations. Researchers must establish biological effects, safety, manufacturing feasibility and clinical benefit before a treatment can be approved.
The government's Sovereign AI programme combines capital with access to compute. Potential Sciences may draw on the national AI Research Resource, which includes the Isambard-AI supercomputer in Bristol. The announcement illustrates Britain's effort to retain scientific AI companies, but whether the investment yields useful medicines or commercial products remains to be seen.